Stockreport

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress [Yahoo! Finance]

BioAtla, Inc.  (BCAB) 
PDF CAB-ROR2 (BA3021) Phase 2 melanoma and squamous cell carcinoma of the head and neck (SCCHN) clinical trials fully enrolled; on track for data readouts in 2Q 2024 CAB- [Read more]